Truist raised the firm’s price target on Doximity (DOCS) to $65 from $49 and keeps a Hold rating on the shares. The company posted results that were likely better than even the most optimistic investor expectations, as the strong outperformance in Q3 benefited from Doximity’s new integrated programs where customers committed larger deal sizes and longer commitment, the analyst tells investors in a research note. The firm adds however that FY25 benefited from market share gains as the pharma industry saw flight to quality.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue